

# Accsys Technologies

Trading update

## Arnhem expansion completed but Hull delayed

General industries

22 September 2022

**Price** 70p/€0.85

**Market cap** £145m/€176m

€1.15/€

Net debt (€m) at 31 March 2022 27.2

Shares in issue 206.6m

Free float 35%

Code AXS

Primary exchange LSE

Secondary exchange Euronext Amsterdam

Accsys's trading update included positive news on the commercial start of the fourth reactor in Arnhem and good progress with construction of the Accoya plant in America for production in Q224. However, this was overshadowed by a larger than expected volume decline in the first five months of FY23 (due to previously reported shutdowns) and more delays and cost overruns in the construction of the Tricoya plant in Hull. We have lowered our estimates and increased the company's risk profile, resulting in a DCF value of €1.21 per share.

Year end	Revenue (€m)	EBITDA* (€m)	Net profit* (€m)	EPS* (€)	EV/sales (x)	EV/EBITDA (x)
03/21	99.8	10.1	1.3	0.01	3.7	36.8
03/22	120.9	10.4	2.1	0.01	3.3	38.2
03/23e	138.5	16.0	6.3	0.03	1.9	16.4
03/24e	183.4	28.8	14.9	0.07	1.3	8.5

Note: \*EBITDA, net profit and EPS are normalised, excluding amortisation of acquired intangibles and exceptional items.

## Update on capacity expansion: Hull further delayed

On its journey to expand capacity from 60,000m<sup>3</sup> last year to 200,000m<sup>3</sup> by 2025, to fulfil the strong market demand for its high-performance wood products, Accsys continued to face problems. The expansion at Arnhem is completed (adding 20,000m<sup>3</sup>) and the construction of the Accoya plant in America is on track, but development of the Tricoya plant in Hull remains problematic. After challenges during construction, there are also disagreements with Accsys's consortium partners about financing cost overruns, which brings uncertainty about when the plant will be operational. Accsys remains committed to working towards commercial production at the Hull plant and our best guess for the start date is now April 2023.

## Higher prices offsetting lower volumes

Accsys indicated that Accoya wood revenues were broadly stable year-on-year at €39m in the first five months of the financial year ending March 2023 (5M23). On 30 June, it communicated that the three reactors in Arnhem had been temporarily shut down in April/May around the completion of construction of the fourth reactor. This resulted in a larger than expected volume decline of 24% to 18,803m<sup>3</sup> in 5M23. However, the decline has been fully compensated by the effect of several sales price increases, including the energy price premium, from 1 May to manage the volatile and significantly higher gas prices in Europe. We have lowered our estimates to include slower volume growth and the delay in Hull.

## Lower valuation on reduced estimates and higher risk

Accsys is trading on EV/sales of 1.9x and EV/EBITDA of 16.4x in FY23e. Our DCF model is based on four reactors in Arnhem and one in Hull, while we add a separate value the Accoya US joint venture (with 100% probability as it is under construction) and the Tricoya project in Malaysia (with 50% probability as a final investment decision has not yet been made). We have raised the company's risk profile by increasing the equity risk premium from 5% to 6%. Together with our lower estimates, this delivers a value of €1.21 per share (previously €1.83).

## Share price performance



%	1m	3m	12m
Abs	(29.2)	(39.9)	(58.6)
Rel (local)	(25.9)	(40.4)	(58.0)

52-week high/low	181p	70p
------------------	------	-----

## Business description

Accsys Technologies is a chemical technology company focused on the development and commercialisation of a range of transformational technologies based on the acetylation of solid wood and wood elements for use as high-performance, environmentally sustainable construction materials.

## Next events

H123 results	November 2022
--------------	---------------

## Analyst

Johan van den Hooven	+44 (0)20 3077 5700
----------------------	---------------------

[industrials@edisongroup.com](mailto:industrials@edisongroup.com)
[Edison profile page](#)

**Accsys Technologies is a research client of Edison Investment Research Limited**

## Mixed news in trading update

---

On 12 September, Accsys published a trading update, with two positive and two negative pieces of news. On the positive side, the fourth reactor in Arnhem is now operational and construction of the Accoya plant in America is on schedule to be operational by April/May 2024. The negatives are the larger than expected volume decline in 5M23 and continued delays with the construction of the first Tricoya plant in Hull, with Accsys in disagreement with its partners about financing.

### No revenue growth in 5M23

Accsys states that Accoya wood sales remained flat year-on-year at €39m in 5M23. Due to the shutdown of all three reactors in Arnhem in April/May as a result of problems with the start-up of the fourth reactor, overall volumes dropped by 24% to 18,803m<sup>3</sup> (considerably more than we expected). Multiple sales price increases over the past 12 months have fully compensated for this volume drop. On 1 May, Accsys also introduced an energy price premium due to volatile and higher gas prices (acetyl raw material costs are linked to the gas price), which continues to provide the company with a mechanism to pass on the effects of higher acetyl costs. The company also has a partial natural hedge through the resale of its by-product.

### Fourth reactor in Arnhem now operational

The fourth reactor in Arnhem increases total capacity by 33%, or by 20,000m<sup>3</sup> to 80,000m<sup>3</sup>. Accsys has started the first commercial batches and will start ramping up production from now on. The goal remains for the fourth reactor to be at full capacity within two years (for comparison, the third reactor was at full capacity in nine months). If the demand for Accoya is as good as Accsys says it is, full capacity could be possible much sooner than the intended two years. Our model takes these two years into account, and at the current price level this provides a turnover of €160m. So, after around a four-month delay for this two-year project, the bigger Arnhem plant is now well underway.

### Construction of Accoya plant in America on schedule

Construction of the Accoya plant in America (with joint venture partner Eastman Chemical Corporation) is on schedule and will take two years from the start in April 2022. This timeframe includes the period of commissioning, thus commercial production could start in April/May 2024. On the positive side, Eastman is overseeing construction of the plant and has a lot of experience in building plants (Accsys has less experience). The construction contract has a fixed price structure, so cost overruns should not be as much of an issue as they have been in Arnhem and Hull. Initial capacity will be 43,000m<sup>3</sup> and we estimate a potential revenue level of €86m at full capacity (at current price levels). At Kingsport, Tennessee, there is potential for total capacity of more than 160,000m<sup>3</sup>, offering ample room for further growth in forthcoming years in America, which is a big potential market for Accoya.

### Prolonged problems in Hull

The first Tricoya plant in Hull is problematic. There is still no agreement with the partners on the financing of €7–10m (on 25 May, Accsys stated that it had sought an extension of the Natwest facility for €3m and, on 30 June, another €4–7m for cost overruns), while in its trading update the company said it is likely that project costs will be higher than the previous estimate of €94–103m on 30 June. According to Accsys, the consortium partners do not want to share the additional costs and apparently prefer not to increase Accsys's stake in the Tricoya UK construction. Accsys provided a bridge loan of €17m last year and has added an uncommitted €8m for these extra expenses (that were announced on 30 June) to allow commissioning of the plant to continue. It has reduced activity levels to cut costs and, according to Accsys, monthly run rate costs were reduced in recent months from around €4m to €1m in September (including the costs of subcontractors). There have also been problems with the software during commissioning, which has added to the

delays. An external expert will investigate the current status of commissioning and the remaining work required to complete and the related costs which are still needed. Accsys will then appeal to the partners again, but it seems unlikely that they will want to share the costs.

Because of Accsys's current liquidity position, there is not much financial room for Accsys to fund new additional costs at Hull on its own. On 25 May, Accsys commented that a total investment of €57m will fall in FY23, being largely the finalisation of the fourth reactor in Arnhem (€8–9m), finalisation of the Hull plant (€15m) and the investment commitment of €28m for the Accoya US joint venture (which will be equity accounted, and therefore these investments are not part of the capex for property, plant and equipment), for which capital was raised in May 2021. More than 90% of the total investments for the company and for the US joint venture are expected to fall in H123. Taking these investments into account, together with the additional bridging loan facility of €8m, our calculations show narrow cash liquidity at the end of the first half. For the company's cash liquidity, it is important to note that the bridging loan facility of €8m to Tricoya UK is uncommitted and Accsys is not under any obligation to lend the full amount and can withdraw it at any stage. According to the company, it currently does meet the covenants, with the most important one for the ABN AMRO facility being net debt/EBITDA, which should reduce over time from 4.0x initially to 2.5x.

Hence there is uncertainty about the amount of additional costs, the financing of these costs and therefore the plant's further progress and pace of construction. Accsys is also looking at what impact the higher gas price will have on Hull's profitability, which it has always said could be EBITDA break-even on 40% capacity. Slower construction may spread the higher costs more evenly, but start-up will take longer. Accsys now says it does not expect Hull to start before year end, but does not doubt the start-up itself. It is looking at all possible options, including changing the structure of the consortium partners or self-funding Hull from Arnhem's incremental cash flows over a longer period. There are currently no plans for another share issue as Accsys raised €19m (net) in May 2022. Hull is planned to have capacity of 40,000m<sup>3</sup> with potential revenue of €50m to be realised within a three-year ramp-up period.

## Estimates lowered

We have reduced our estimates after the lower than expected 5M23 revenue level and further delays in Hull. There is also uncertainty about when the plant in Hull will start up. We have reduced our FY23 revenue estimate by 10% and our EBITDA estimate by 20% (larger decline due to operating leverage and the impact of higher input prices) but, as we expect Hull to come on stream in the next financial year and Arnhem being operational for the full year, the adjustments are less pronounced for FY24 (-3% for revenues and -14% for EBITDA). These lower estimates reflect revenue growth of 15% in FY23 and 32% in FY24, driven by additional capacity and pricing, while EBITDA margins are expected to improve, driven by scale benefits and pricing.

**Exhibit 1: Change in P&L estimates**

€m	FY23e			FY24e			FY25e (new)
	Old	New	Change	Old	New	Change	
Sales	153.9	138.5	-10.1%	189.3	183.4	-3.2%	219.2
Gross margin	30.4%	29.7%		32.7%	30.7%		32.0%
EBITDA normalised	20.0	16.0	-19.9%	33.4	28.8	-13.8%	39.7
EBITDA margin	13.0%	11.6%		17.6%	15.7%		18.1%
Net profit (reported)	9.1	6.3	-30.3%	19.1	14.9	-21.9%	22.4
Net profit (normalised)	9.1	6.3	-30.3%	19.1	14.9	-21.9%	22.4

Source: Edison Investment Research

Despite the short-term uncertainty, there is long-term potential, with the fourth reactor in Arnhem adding 20,000m<sup>3</sup> of capacity from now, the Hull plant adding 40,000m<sup>3</sup> potentially from April 2023 and the Accoya plant in America adding 43,000m<sup>3</sup> from April/May 2024, bringing total capacity to

160,000m<sup>3</sup>. With four full reactors in Arnhem, one in Hull and two in America, potential revenues on a fully consolidated basis are €296m versus the €121m reported in FY22.

## **Lower valuation on reduced estimates and higher risk**

---

We use a discounted cash flow (DCF) model as there are no other listed companies with a business profile close to Accsys's. The company is trading at 1.9x EV/sales and 16.4x EV/EBITDA in FY23e.

Our DCF model is based on four reactors in the Arnhem plant and one in Hull. We use a DCF to value separate Accoya and Tricoya plants and add a value for the Accoya plant in the US, which is expected to be operational in mid-2024. We also add a value for the Tricoya plant in Malaysia (or an alternative location) with a probability rate of only 50% as the final investment decision on that project has not yet been taken. An investment decision will be taken after the Tricoya plant in Hull has been operational for at least six months, so timing is currently uncertain but it will be delayed until at least Q3/Q423.

Most of our assumptions for the DCF model are unchanged except for the equity risk premium, which we increase from 5% to 6% to reflect the short-term uncertainties. This lifts our WACC from 8.9% to 10.0%. On our lower estimates and the increased risk profile, our DCF indicates a value per share of €1.21 per share (previously €1.83).

**Exhibit 2: Financial summary**

€m	FY21	FY22	FY23e	FY24e	FY25e
31-March	IFRS	IFRS	IFRS	IFRS	IFRS
<b>INCOME STATEMENT</b>					
Revenue (reported)	99.8	120.9	138.5	183.4	219.2
Gross Profit	33.1	36.0	41.1	56.4	70.1
EBITDA normalised	10.1	10.4	16.0	28.8	39.7
EBITDA reported	10.2	10.3	16.0	28.8	39.7
Depreciation & Amortisation	(5.7)	(6.2)	(7.7)	(8.5)	(8.8)
EBIT normalised	4.4	4.2	8.4	20.3	30.9
Exceptionals (Edison definition)	0.1	(0.1)	0.0	0.0	0.0
EBIT reported	4.5	4.1	8.4	20.3	30.9
Net Interest	(4.1)	(2.3)	(3.0)	(3.5)	(4.0)
Results of associates	(0.1)	0.0	0.0	0.0	0.0
Profit Before Tax	0.3	1.8	5.4	16.8	26.9
Reported tax	(1.3)	(1.0)	(0.5)	(1.7)	(2.7)
Profit After Tax	(0.9)	0.7	4.9	15.1	24.2
Minority interests	1.4	1.6	1.5	(0.2)	(1.8)
Net profit (normalised)	1.3	2.1	6.3	14.9	22.4
Net profit (reported)	0.3	2.4	6.3	14.9	22.4
Average number of shares (m)	164.9	178.9	204.3	206.6	206.6
Average number of shares, diluted (m)	173.3	185.9	211.3	213.6	213.6
EPS normalised (€)	0.01	0.01	0.03	0.07	0.11
EPS normalised diluted (€)	0.00	0.01	0.03	0.07	0.10
EPS reported (€)	0.00	0.01	0.03	0.07	0.11
DPS (€)	0.00	0.00	0.00	0.00	0.03
Revenue growth	9.8%	21.1%	14.6%	32.4%	19.5%
Gross Margin	33.2%	29.8%	29.7%	30.7%	32.0%
Normalised EBITDA Margin	10.1%	8.6%	11.6%	15.7%	18.1%
Normalised Operating Margin	4.4%	3.5%	6.1%	11.1%	14.1%
Reported EBIT margin	4.5%	3.4%	6.1%	11.1%	14.1%
<b>BALANCE SHEET</b>					
Fixed Assets	155.6	195.3	247.7	246.0	242.5
Intangible Assets	10.9	10.8	10.8	10.8	10.7
Tangible Assets	144.4	181.3	205.7	204.0	200.6
Investments & other	0.3	3.2	31.2	31.2	31.2
Current Assets	72.5	79.8	55.7	86.7	126.4
Stocks	12.3	20.4	23.3	30.9	36.9
Debtors	9.8	13.2	13.6	16.2	19.3
Other current assets	2.8	4.2	4.7	6.1	7.1
Cash & cash equivalents	47.6	42.1	14.1	33.5	63.0
Current Liabilities	42.3	45.7	46.8	56.9	64.5
Creditors	9.5	16.7	17.2	22.3	26.1
Other current liabilities	22.2	16.4	16.9	22.0	25.7
Short term borrowings	10.6	12.7	12.7	12.7	12.7
Long Term Liabilities	49.2	56.5	56.5	56.5	56.5
Long term borrowings	49.2	56.5	56.5	56.5	56.5
Other long-term liabilities	0.0	0.0	0.0	0.0	0.0
Shareholders' equity	136.6	172.9	200.2	219.2	247.9
Minority interests	37.2	35.5	35.5	35.5	35.5
Balance sheet total	228.1	275.1	303.5	332.7	368.9
<b>CASH FLOW</b>					
Op Cash Flow before WC and tax	10.2	10.3	16.0	28.8	39.7
Working capital	8.3	(9.2)	(2.8)	(1.4)	(2.6)
Exceptional & other	(1.9)	(1.5)	3.5	4.0	4.5
Tax	0.1	0.1	(0.5)	(1.7)	(2.7)
Net interest	3.4	2.9	(3.0)	(3.5)	(4.0)
Net operating cash flow	20.1	2.6	13.1	26.2	34.9
Capex	(12.4)	(45.3)	(32.0)	(6.8)	(5.3)
Investments in financial assets/joint ventures	(1.1)	(3.8)	(28.0)	0.0	0.0
Equity financing	9.4	34.9	19.0	0.0	0.0
Dividends	0.0	0.0	0.0	0.0	0.0
Other	(3.9)	(3.3)	0.0	0.0	0.0
Net Cash Flow	12.1	(14.9)	(27.9)	19.4	29.5
Opening net debt/(cash), including lease	24.3	12.2	27.2	55.1	35.7
Closing net debt/(cash), including lease	12.2	27.2	55.1	35.7	6.2

Source: Accsys Technologies, Edison Investment Research

## General disclaimer and copyright

This report has been commissioned by Accsys Technologies and prepared and issued by Edison, in consideration of a fee payable by Accsys Technologies. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

## United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

## United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960  
Schumannstrasse 34b  
60325 Frankfurt  
Germany

London +44 (0)20 3077 5700  
280 High Holborn  
London, WC1V 7EE  
United Kingdom

New York +1 646 653 7026  
1185 Avenue of the Americas  
3rd Floor, New York, NY 10036  
United States of America

Sydney +61 (0)2 8249 8342  
Level 4, Office 1205  
95 Pitt Street, Sydney  
NSW 2000, Australia